A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer-Reference-Cited by-同舟云学术

A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer

Published:2022-07-01 Issue:7 Volume:32 Page:799-806
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Lee Nancy Y.¹,Riaz Nadeem¹,Wu Vanessa¹,Brinkman Thomas¹,Tsai Chiaojung J.¹,Zhi Wanquing²^ORCID,Fetten James²,Ho Alan²^ORCID,Wong Richard J.³,Ghossein Ronald⁴,Tuttle Michael⁵,Fagin James⁵^ORCID,Pfister David G.²,Sherman Eric²

Affiliation:

1. Department of Radiation Oncology, MSKCC, New York, New York, USA.

2. Division of Head and Neck Medical Oncology, Department of Medicine, MSKCC, New York, New York, USA.

3. Department of Surgery, MSKCC, New York, New York, USA.

4. Department of Pathology, MSKCC, New York, New York, USA.

5. Endocrine Service, Department of Medicine, MSKCC, New York, New York, USA.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2022.0050